

PROVINCIAL FUNDING SUMMARY

Bevacizumab (Avastin) in combination with Capecitabine for metastatic colorectal cancer (pCODR 10055)

pERC Recommendation: Recommends with condition on the cost-effectiveness being improved to an acceptable level

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: August 6, 2015

This information is current as of October 1, 2019.

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Nov 1, 2018	<p>First line therapy for metastatic or unresectable colorectal adenocarcinoma in a patient not suitable for combination chemotherapy with irinotecan or oxaliplatin, and for metastatic adenocarcinoma of the appendix or small bowel.</p> <ul style="list-style-type: none"> • No major surgery within 28 days of administration of therapy • No untreated CNS metastases • ECOG performance status 0-2 • Adequate hematologic, renal and hepatic function (Caution in patients with severe hepatic dysfunction ie. total bilirubin greater than 50 micromol/L) • Expected survival greater than 3 months (Caution in patients with: 1) recent MI; 2) uncontrolled angina, hypertension, cardiac arrhythmias, congestive heart failure, 3) renal disease including proteinuria, 4) bleeding disorders, 5) previous anthracycline exposure, or 6) other serious medical illness • Caution in patients with recent (less than 6 months) arterial thromboembolic event • Note: this is for first line therapy only and all requests for other uses will still require an approval through the BC Cancer Compassionate Access Program (CAP)
AB	Under provincial consideration*		

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
SK	Funded	Sept 1, 2017	In combination with a fluoropyrimidine (Capecitabine or Fluorouracil/Leucovorin) for the first-line treatment of patients with advanced or metastatic colorectal cancer for whom combination chemotherapy with Oxaliplatin or Irinotecan is unsuitable, and who have an ECOG performance status of <2.
MB	Funded	Sept 1, 2017	Bevacizumab in combination with capecitabine or 5-fluorouracil/leucovorin (de Gramont regimen) for the first line treatment of patients with advanced or metastatic colorectal cancer for whom combination chemotherapy with oxaliplatin or irinotecan is unsuitable and patient has ECOG performance status of 2 or less.
ON	Funded	Oct 20, 2017	Bevacizumab is used in combination with a fluoropyrimidine (AVEX) for the first-line treatment of patients with metastatic colorectal, small bowel, or appendiceal cancer for whom combination chemotherapy with oxaliplatin or irinotecan is unsuitable, and the patient has ECOG Performance Status < 2.
NS	Under provincial consideration*		
NB	Funded	Jan 9, 2018	In combination with a fluoropyrimidine, for the first line treatment of patients with advanced or metastatic colorectal cancer for whom combination chemotherapy with oxaliplatin or irinotecan is unsuitable.
NL	Under provincial consideration*		
PEI	Under provincial consideration*		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.